seelos therapeutics announces the signing of a material transfer agreement with u.s. army medical materiel development activity (usammda) to evaluate sls-002 for treatment of ptsd
-Dosing of the SLS-002 cohort is expected to commence in 4Q2024 NEW YORK, Sept. 24, 2024 /PRNewswire/ -- Seelos Therapeutics,...